BioMerieux (XPAR:BIM) Construction In Progress : €250 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is BioMerieux Construction In Progress?

BioMerieux's quarterly construction in progress declined from Dec. 2022 (€227 Mil) to Jun. 2023 (€218 Mil) but then increased from Jun. 2023 (€218 Mil) to Dec. 2023 (€250 Mil).

BioMerieux's annual construction in progress increased from Dec. 2021 (€157 Mil) to Dec. 2022 (€227 Mil) and increased from Dec. 2022 (€227 Mil) to Dec. 2023 (€250 Mil).

BioMerieux Construction In Progress Historical Data

The historical data trend for BioMerieux's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMerieux Construction In Progress Chart

BioMerieux Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

185.30

130.00

157.10

227.10

249.60

BioMerieux Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Construction In Progress	Get a 7-Day Free Trial															157.10	197.20	227.10	218.30	249.60

BioMerieux Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

BioMerieux (XPAR:BIM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (XPAR:BIM) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

BMXMF:USA BIMp:UK 0RUG:UK EYWN:Germany BIM:Austria

Address

Marcy l’Etoile, Lyon, FRA, 69280

Website

http://www.biomerieux.com

BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France.

BioMerieux (XPAR:BIM) Headlines

No Headlines